Market Place
Sourcing Support
OncoC4 and AcroImmune Announce Merger
25 Sep 2024 //
GLOBENEWSWIRE
OncoC4 Doses First Patient In ONC-841 Solid Tumor Trial
04 Sep 2024 //
GLOBENEWSWIRE
OncoC4 Gets FDA IND Clearance For SIGLEC10 Inhibitor ONC-841 In Solid Tumors
23 Apr 2024 //
GLOBENEWSWIRE
OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee
02 Apr 2024 //
GLOBENEWSWIRE
OncoC4 Announces First Patient Dosed in Ph 1/2 Trial of BNT316/ONC-392 Program
22 Feb 2024 //
GLOBENEWSWIRE
OncoC4 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
GLOBENEWSWIRE
OncoC4 has Appointed of Abid Ansari as Chief Financial Officer
28 Sep 2023 //
GLOBENEWSWIRE
BioNTech and OncoC4 Present Positive Phase 1/2 Data for BNT316/ONC-392
02 Jun 2023 //
PRESS RELEASE
BioNTech signs deal to co-develop OncoC4`s cancer drug
21 Mar 2023 //
REUTERS
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Ph2 Trial of ONC-392
30 Dec 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.